Celsion is focused on the development and commercialization of innovative cancer drugs. These include tumor-targeting treatments using focused heat energy in combination with heat-activated liposomal drug technology. The company has research, license, or commercialization agreements with the National Institutes of Health and a number of universities around the world.
The company announced today that Ronnie T.P. Poon, MD, MS, PhD, FRCS, FACS, Professor of Surgery at the University of Hong Kong and Lead Asia Pacific Principal Investigator for Celsion’s Phase III HEAT Study of ThermoDox in hepatocellular carcinoma will present the clinical trial results at the International Liver Cancer Association seventh annual conference being held in Washington D.C. September 14, 2013.
This association is the only international organization devoted solely on liver cancer research for experts from the medical, surgical oncology, interventional, and hepatology disciplines. Two members of the executive committee – Dr. Morris Sherman and Professor Riccardo Lencioni – along with Dr. Poon are the principal investigators on the Phase III HEAT Study of ThermoDox.
Celsion has conducted a thorough analysis of the data from the Phase III study on approximately 300 patients with primary liver cancer. Data coming to light from the HEAT Study demonstrates that ThermoDox markedly improves positive progression free survival and overall survival in patients if their lesions undergo radio-frequency ablation for 45 minutes or more in combination with ThermoDox, which is thermally sensitive liposomal doxorubicin (releasing the drug at a few degrees above body temperature).
Further information about Celsion Corporation, ThermoDox, and other products in development can be found at www.celsion.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website
http://www.missionir.com/disclaimer.html
